{"schemaVersion":1,"research":true,"symbol":"rvty","name":"Revvity","topic":"moat","path":"/stock/rvty/moat","status":"published","version":3,"updatedAt":"2026-10-18T14:27:20.861Z","locked":false,"publicFairValue":false,"fairValue":null,"moat":{"verdict":"uncertain","summary":"Revvity has proprietary technologies and workflow software with demonstrated renewals, but the passages do not establish durable protection against substitution across the business. Pricing actions partly offset costs in 2023–2024, demonstrating some realized pricing flexibility. Subsequent tariff and diagnostic mix pressures show limits to resilience. These disclosures establish plausible advantages, but neither a company-wide narrow moat nor a demonstrated absence of one.","advantages":[{"mechanism":"switching_costs","claim":"Scientific workflow integration and recurring software relationships are plausible sources of switching friction. Actual contract renewals support repeat demand, but migration costs and customer dependence are not established.","durability":"Renewals and noncancelable subscriptions support existing commercial relationships. Their duration and protection against replacement remain uncertain; disclosed longer-duration remaining obligations are immaterial.","risks":"Technological change and capable competitors can reduce workflow relevance. Deferred revenue growth can reflect new business, acquisitions or billing timing rather than improved retention.","invalidation":"The proposed mechanism would be undermined by sustained renewal losses, customers migrating workflows without material disruption, or recurring software demand declining despite stable end markets.","competitors":[],"evidenceIds":["q17","q20","q851","q422","q423","q430"],"counterEvidenceIds":["q323","q429"]},{"mechanism":"intangible_assets","claim":"Owned patents, proprietary know-how and licensed technologies provide current technical assets. Their effectiveness as durable barriers is asserted by management rather than demonstrated through exclusivity outcomes or sustained competitive wins.","durability":"No patent-expiration schedule, protected revenue share or demonstrated exclusion of alternatives is supplied. Continued innovation and access to licensed technology are necessary.","risks":"Competitors possess substantial intellectual property and development resources. Patents can expire or be challenged, and licensed rights can be lost.","invalidation":"The proposed advantage would be undermined by commercially successful substitutes bypassing protected technology, loss of important licensed rights, or sustained share losses in products dependent on proprietary technology.","competitors":[],"evidenceIds":["q28","q30","q32"],"counterEvidenceIds":["q323","q357","q360","q364"]}],"evidence":[{"id":"q17","sourceId":"filing-1","location":"Business / Katalyst D2D software","excerpt":"◦Katalyst D2D® software provides integrated experiment design, planning, execution, and analysis capabilities supporting high-throughput synthesis, process optimization, and preformulation studies."},{"id":"q20","sourceId":"filing-1","location":"Business / Luminata software","excerpt":"The software constructs process maps for visualization of impurities at each route stage, stores experimental context and expert interpretations, and enables rapid assessment of impurity control effectiveness."},{"id":"q28","sourceId":"filing-1","location":"Business / Intellectual Property","excerpt":"Intellectual Property We own numerous United States and foreign patents and have patent applications pending in the United States and abroad."},{"id":"q30","sourceId":"filing-1","location":"Business / Intellectual Property","excerpt":"In addition to our patent portfolio, we possess a wide array of unpatented proprietary technology and know-how."},{"id":"q32","sourceId":"filing-1","location":"Business / Intellectual Property / management assessment","excerpt":"We believe that patents and other proprietary rights are important to the development of both of our reporting segments, but we also rely upon trade secrets, know-how, continuing technological innovations and licensing opportunities to develop and maintain the competitive position of both of our reporting segments."},{"id":"q65","sourceId":"filing-1","location":"MD&A / Fiscal 2025 consolidated gross margin","excerpt":"Our consolidated gross margin decreased 104 basis points in fiscal year 2025, as compared to fiscal year 2024, primarily due to increased tariffs, unfavorable changes in foreign exchange rates, and product mix shift, partially offset by the completion of product rebranding efforts in fiscal year 2024."},{"id":"q66","sourceId":"filing-1","location":"MD&A / Fiscal 2025 consolidated operating margin","excerpt":"Our consolidated operating margin decreased 10 basis points in fiscal year 2025, as compared to fiscal year 2024, due to gross margin headwinds, as discussed above, partially offset by productivity and cost containment initiatives."},{"id":"q68","sourceId":"filing-1","location":"MD&A / Fiscal 2025 revenue","excerpt":"Consolidated Results of Operations Fiscal Year 2025 Compared to Fiscal Year 2024 Revenue Revenue for fiscal year 2025 was $2,856.1 million, as compared to $2,755.0 million for fiscal year 2024, an increase of $101.1 million, or 4%, which includes an approximate 1% increase in revenue attributable to favorable changes in foreign exchange rates."},{"id":"q86","sourceId":"filing-1","location":"MD&A / Diagnostics fiscal 2025 operating margin","excerpt":"Segment operating margin decreased 194 basis points to 24.2% in fiscal year 2025, as compared to 26.1% in fiscal year 2024, primarily due to increased tariffs, unfavorable changes in foreign exchange rates, and product mix shift due to China diagnostic testing policy changes."},{"id":"q94","sourceId":"filing-1","location":"Liquidity and Capital Resources / completed repurchases","excerpt":"During fiscal year 2025, we repurchased 7,264,299 shares of common stock under the Repurchase Program for an aggregate cost of $695.4 million."},{"id":"q95","sourceId":"filing-1","location":"Liquidity and Capital Resources / completed repurchases","excerpt":"During fiscal year 2025, we repurchased 1,245,232 shares of common stock under the New Repurchase Program for an aggregate cost of $120.5 million."},{"id":"q293","sourceId":"filing-2","location":"Note 10 / first-half 2026 completed repurchases","excerpt":"During the six months ended July 5, 2026, the Company repurchased 877,445 shares of common stock under the Repurchase Program for an aggregate cost of $86.9 million."},{"id":"q288","sourceId":"filing-2","location":"Note 4 / restructuring costs","excerpt":"Restructuring and other costs, which are included in the selling, general and administrative expenses in the consolidated statements of operations, by segment were as follows: Three Months Ended Six Months Ended July 5, 2026 June 29, 2025 July 5, 2026 June 29, 2025 (In thousands) Life Sciences $ 5,926 $ 1,917 $ 9,155 $ 4,445 Diagnostics 29,582 9,233 37,136 9,368 Corporate — 53 (108) 629 $ 35,508 $ 11,203 $ 46,183 $ 14,442 The following table summarizes the changes in the Company’s accrued restructuring balance for the six months ended July 5, 2026."},{"id":"q314","sourceId":"filing-2","location":"MD&A / first-half 2026 gross margin","excerpt":"As a percentage of revenue, cost of revenue decreased to 44.2% for the six months ended July 5, 2026, from 44.5% for the six months ended June 29, 2025, resulting in an increase in gross margin of 40 basis points to 55.8% for the six months ended July 5, 2026, from 55.5% for the six months ended June 29, 2025, primarily due to tariff refunds and product mix shift."},{"id":"q318","sourceId":"filing-2","location":"MD&A / tariff refunds received","excerpt":"Through the established CBP refund process, the Company applied for $20.2 million of refunds and received $16.2 million through July 5, 2026."},{"id":"q323","sourceId":"filing-2","location":"Risk Factors / competing businesses' capabilities","excerpt":"Many of the businesses competing with us in these industries have significant financial and other resources to invest in new technologies, substantial intellectual property portfolios, substantial experience in new product development, regulatory expertise, manufacturing capabilities, and established distribution channels to deliver products to customers."},{"id":"q357","sourceId":"filing-2","location":"Risk Factors / patent expiration","excerpt":"37 Table of Contents The expiration of our previously issued patents may cause us to lose a competitive advantage in certain of the products and services we provide."},{"id":"q360","sourceId":"filing-2","location":"Risk Factors / patent challenges and circumvention","excerpt":"Third parties have in the past and may in the future also challenge the validity of our issued patents, may circumvent or “design around” our patents and patent applications, or claim that our products, processes or technologies infringe their patents."},{"id":"q364","sourceId":"filing-2","location":"Risk Factors / loss of licensed rights","excerpt":"If we are unable to renew our licenses or otherwise lose our licensed rights, we may have to stop selling products or we may lose competitive advantage."},{"id":"q371","sourceId":"filing-2","location":"Risk Factors / implemented tariff mitigation","excerpt":"While we have implemented mitigation strategies including manufacturing optimization, supplier collaboration, pricing adjustments, and temporary cost measures, these actions may not fully offset the impact of existing or future tariffs."},{"id":"q422","sourceId":"filing-2","location":"Revenue recognition / deferred revenue composition","excerpt":"The deferred revenue balance is primarily related to the Company’s software as a service offerings, maintenance contracts and prepaid storage arrangements."},{"id":"q423","sourceId":"filing-2","location":"Revenue recognition / July 2026 deferred revenue","excerpt":"Deferred revenue totaled $239.8 million at July 5, 2026, of which $174.3 million was included in “Accrued expenses and other current liabilities” and $65.5 million was included in “Deferred taxes and other long-term liabilities” in the condensed consolidated balance sheet."},{"id":"q429","sourceId":"filing-2","location":"Revenue recognition / remaining performance obligations","excerpt":"The estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the period are not material to the Company."},{"id":"q430","sourceId":"filing-2","location":"Revenue recognition / noncancelable customer contracts","excerpt":"The remaining performance obligations primarily include noncancelable purchase orders, noncancelable software subscriptions and cloud service contracts and long-term prepaid storage contracts."},{"id":"q432","sourceId":"filing-2","location":"Note 3 / acquisition cash payment and contingent commitment","excerpt":"(“ACD/Labs”) for $72.0 million in cash paid at closing and up to $8.0 million in contingent consideration to be paid in cash based on the achievement of certain revenue metrics through 2028."},{"id":"q458","sourceId":"filing-2","location":"Liquidity and Capital Resources / operating cash flow","excerpt":"Operating Activities. Net cash provided by operating activities of our continuing operations was $317.8 million for the six months ended July 5, 2026, as compared to $268.4 million for the six months ended June 29, 2025, an increase of $49.4 million."},{"id":"q495","sourceId":"filing-3","location":"Proxy / Corporate Governance Highlights","excerpt":"Compensation & Benefits; Nominating & Corporate Governance Yes Pascale Witz 59 2017 Founder and President of PWH Advisors Audit; Compensation & Benefits Yes ii Revvity • 2026 Proxy Statement Table of Contents Corporate Governance Highlights The following table summarizes our board structure and key elements of our corporate governance framework: Size of Board Ten Number of Independent Directors Nine Independent Chair Yes Board Self-Evaluation Annual Review of Independence of Board Annual Independent Directors Meet Without Management Present Yes Structure of Board Non-Classified Voting Standard for Election of Directors in Uncontested Elections Majority of Shares Cast Wide Range of Backgrounds, Experiences and Skills Yes Corporate Governance Guidelines Yes Fiscal 2025 Business Highlights We overcame a dynamic market environment throughout 2025, ultimately exceeding our financial targets provided at the beginning of the year."},{"id":"q544","sourceId":"filing-3","location":"Proxy / Securities Trading Policy","excerpt":"In addition to prohibiting trading while in possession of material non-public information, our Securities Trading Policy prohibits all employees and members of our board from engaging in the following types of transactions with respect to our securities: • engaging in “short” sales and “selling against the box”; or • trading in puts, calls, straddles, options or any other form of derivative securities; or • directly or indirectly engaging in hedging or monetization activities with respect to our securities including through purchases of financial instruments (such as prepaid variable forward contracts, equity swaps, collars and exchange funds) or other transactions that hedge or offset, or are designed to hedge or offset, any decrease in the market value of our securities."},{"id":"q575","sourceId":"filing-3","location":"Compensation Discussion and Analysis / granted 2025 incentives","excerpt":"Half (50%) of the long-term incentive compensation granted to our named executive officers in fiscal 2025 will vest based solely upon the achievement of financial performance metrics."},{"id":"q578","sourceId":"filing-3","location":"Compensation Discussion and Analysis / 2025 equity vehicles","excerpt":"To align the interests of executive officers with shareholders and to support an ownership culture, 100% of the named executive officers’, including the Chief Executive Officer’s, 2025 target long-term incentive compensation opportunity was provided using equity-based vehicles (PRSUs, RSUs and stock options)."},{"id":"q584","sourceId":"filing-3","location":"Compensation Discussion and Analysis / 2025 LTIP metrics","excerpt":"The metrics of our 2025 LTIP program are organic revenue growth, free cash flow conversion, and adjusted operating margin expansion."},{"id":"q624","sourceId":"filing-3","location":"Compensation Discussion and Analysis / approved 2025 bonuses","excerpt":"Singh $ 1,539,000 124 % $ 1,908,360 125 % $ 2,385,450 155 % Maxwell Krakowiak $ 420,000 124 % $ 520,800 115 % $ 598,920 143 % Joel S."},{"id":"q666","sourceId":"filing-3","location":"Proxy / existing proxy access rights","excerpt":"• Our By-laws provide for proxy access, which permits shareholders, or a group of up to 20 shareholders, owning 3% or more of our outstanding shares of common stock continuously for at least three years, to nominate and include in our proxy materials nominees for director 82 Revvity • 2026 Proxy Statement Table of Contents constituting up to 20% of the board or two directors, whichever is greater, subject to the requirements set forth in our By-laws."},{"id":"q851","sourceId":"filing-4","location":"MD&A / fiscal 2024 software renewals and new orders","excerpt":"The decrease in Life Sciences segment revenue was driven by a decrease in instruments and reagents revenue due to pharmaceutical and biotechnology market headwinds, partially offset by an increase in software revenue from the timing of contract renewals and new orders."},{"id":"q852","sourceId":"filing-4","location":"MD&A / fiscal 2024 realized pricing contribution","excerpt":"Our consolidated gross margin decreased 16 basis points in fiscal year 2024, as compared to fiscal year 2023, primarily due to an unfavorable shift in product mix and higher product costs, partially offset by pricing actions and productivity initiatives."},{"id":"q1055","sourceId":"filing-5","location":"MD&A / fiscal 2023 realized pricing contribution","excerpt":"Our consolidated gross margins decreased 411 basis points in fiscal year 2023, as compared to fiscal year 2022, primarily due to lower revenue from COVID-19 product offerings, and an unfavorable shift in product mix, partially offset by pricing actions."}],"changes":["Retain the previous uncertain verdict: additional evidence establishes renewals and contractual relationships but does not establish durable company-wide barriers.","Strengthen the pricing assessment because 2023 and 2024 operating disclosures explicitly identify pricing actions as partial offsets to gross-margin pressure.","Add first-half 2026 results, distinguishing tariff-refund benefits from customer-funded pricing resilience.","Assess management using actual proxy disclosures and completed spending, rather than leaving alignment and governance unsupported."],"limitations":["All supplied sources are issuer filings. Operating results and contractual disclosures support numerical assessments, while product superiority and competitive-position statements remain management assertions.","No operating competitors are named as such in the relevant passages. Suppliers, acquisition targets and directors' other affiliations do not establish competitor coverage.","No customer migration costs, retention rates, protected revenue shares, competitive win rates or patent-expiration coverage are supplied.","Price realization is described directionally; price-volume decomposition, customer responses and contractual repricing provisions are absent.","The proxy passages alleging substitution toward cheaper diagnostic tests and misconduct appear in shareholder-proposal material; they are not treated as verified management operating disclosures or adjudicated findings.","The 2026 proxy establishes existing governance arrangements and granted 2025 awards. Proposed special-meeting amendments are not treated as adopted, and unvested awards are not treated as vested.","Actual executive beneficial ownership and compliance with ownership guidelines are not established by the supplied passages.","Source dates are filing dates, retaining dateKind filed. Fiscal results are assessed for their stated reporting periods; acquisition accounting lives are not assumed to measure moat durability."],"qualityAssessments":[{"category":"moat","checks":[{"criterion":"structural_advantage","grade":null,"rationale":"Proprietary assets and integrated workflows establish plausible mechanisms, but their effectiveness against substitution is insufficiently demonstrated.","evidenceIds":["q17","q20","q28","q30","q323"]},{"criterion":"durability","grade":null,"rationale":"The evidence does not establish the duration of competitive protection. Patent expiration and license risks identify possible erosion rather than prove realized failure.","evidenceIds":["q357","q364","q429"]},{"criterion":"customer_dependency","grade":null,"rationale":"Renewals and noncancelable subscriptions establish customer relationships, but do not establish dependence or material costs of replacement across Revvity.","evidenceIds":["q851","q430"]},{"criterion":"erosion_resilience","grade":null,"rationale":"Revenue growth and cost mitigation coexist with diagnostic policy and mix pressures. Their implications for durable competitive protection remain unresolved.","evidenceIds":["q68","q66","q86","q323"]}]},{"category":"pricing_power","checks":[{"criterion":"realized_pricing","grade":2,"rationale":"Pricing actions partly offset gross-margin pressures in both 2023 and 2024, establishing realized benefits. Later adjustments are disclosed, but their magnitude and customer response are absent; strong pricing power is unproven.","evidenceIds":["q1055","q852","q371"]},{"criterion":"retention","grade":2,"rationale":"Actual software renewals, prepaid service relationships and noncancelable subscriptions support repeat demand. This is indirect operating evidence, without a renewal rate or proof of broad customer dependence.","evidenceIds":["q851","q422","q423","q430","q429"]},{"criterion":"margin_resilience","grade":2,"rationale":"Productivity limited the 2025 operating-margin decline to 10 basis points despite a 104-basis-point gross-margin decline. Diagnostics experienced greater pressure, and first-half 2026 improvement benefited from tariff refunds and mix. Resilience is mixed and cannot be attributed principally to pricing.","evidenceIds":["q65","q66","q86","q314","q318"]},{"criterion":"contractual_freedom","grade":null,"rationale":"Implemented pricing actions show some practical flexibility, but the passages do not establish contractual rights to reset customer prices or terms. Noncancelability does not establish repricing freedom.","evidenceIds":["q371","q430"]}]},{"category":"strong_management","checks":[{"criterion":"capital_discipline","grade":2,"rationale":"Completed 2025 repurchases totaled $815.9 million; first-half 2026 repurchases were $86.9 million alongside a $72 million acquisition payment and contingent commitments. First-half operating cash flow rose to $317.8 million, but acquisition returns, repurchase value creation and full funding needs are not established.","evidenceIds":["q94","q95","q293","q432","q458"]},{"criterion":"incentive_alignment","grade":2,"rationale":"Granted equity incentives, performance-linked vesting, cash-conversion metrics and hedging restrictions support alignment. Discretionary individual bonus uplifts and missing actual ownership evidence limit the assessment. Granted awards are not assumed to have vested.","evidenceIds":["q575","q578","q584","q544","q624"]},{"criterion":"execution","grade":2,"rationale":"Reported 2025 revenue growth, limited consolidated operating-margin erosion and improved first-half 2026 operating cash flow support execution indirectly. Diagnostic weakness, increased restructuring charges and refund-assisted gross-margin improvement make the record mixed.","evidenceIds":["q68","q66","q86","q458","q288","q314"]},{"criterion":"governance","grade":3,"rationale":"The proxy discloses nine independent directors out of ten, an independent chair, a nonclassified board, majority voting, existing proxy access and restrictions on hedging. These are strong demonstrated governance arrangements, without establishing exceptional long-term effectiveness or adoption of proposed amendments.","evidenceIds":["q495","q666","q544"]}]}],"financialAssessments":[],"qualityPolicy":"quality-scores-2","sourcePolicy":"issuer-evidence-4","basisHash":"5e7ecfaa7eb1600ae171806c7cfad56b5c2ebbe6d53a071bd04a46668823f95d","updatedAt":"2026-10-18T14:27:20.861Z","sources":[{"id":"filing-1","url":"https://www.sec.gov/Archives/edgar/data/31791/000003179126000012/revv-20251228.htm","publishedAt":"2026-02-24","sha256":"c642f0c908f15dbd2350c53f477c1df43cbfb162ad545a55b2526e503bd4c932","dateKind":"filed"},{"id":"filing-2","url":"https://www.sec.gov/Archives/edgar/data/31791/000003179126000027/revv-20260705.htm","publishedAt":"2026-08-11","sha256":"5da708bd4d45300ef68123365a11a95e886681070df018615f8b74012a2bc3aa","dateKind":"filed"},{"id":"filing-3","url":"https://www.sec.gov/Archives/edgar/data/31791/000119312526107266/d21831ddef14a.htm","publishedAt":"2026-03-16","sha256":"8287f26bebadccfcc8d32d1e94f4eafa135d52fcd3503d25b8839a731ec15222","dateKind":"filed"},{"id":"filing-4","url":"https://www.sec.gov/Archives/edgar/data/31791/000003179125000009/revv-20241229.htm","publishedAt":"2025-02-25","sha256":"c838ee1bb035f06729c3dedd86079146489fcfdaf877dd74956770e212991cb0","dateKind":"filed"},{"id":"filing-5","url":"https://www.sec.gov/Archives/edgar/data/31791/000003179124000004/pki-20231231.htm","publishedAt":"2024-02-27","sha256":"bd2b0d6f8d45a04e67c481517e65fe36d6a7bf9ae46264f22587b90f02f8833d","dateKind":"filed"},{"id":"filing-6","url":"https://www.sec.gov/Archives/edgar/data/31791/000003179126000019/revv-20260405.htm","publishedAt":"2026-05-12","sha256":"7032cd4d5f7dc3a6c9a267421feaa774cebf523663133070c666a40e6c49e683","dateKind":"filed"}],"model":"gpt-6.1-sol","providerId":"codex:d77fd337534c2a63381b78478abd44e49fcc8b13c04cf4b0efaa59a440bafbbf","usage":{"input_tokens":86966,"cached_input_tokens":0,"cache_write_input_tokens":0,"output_tokens":3572,"reasoning_output_tokens":174}},"signals":[{"period":"2021","end":"2022-01-02","values":{"gross_margin":48.034454741888425,"operating_margin":26.29432726636905,"roic":11.668411042593542,"fcf_margin":25.8697114700536,"sbc_revenue":0.6469095465337746},"issues":{"software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","roic_wacc":"Enter a WACC assumption from 0 to 100%.","interest_coverage":"The reported inputs required for this metric are unavailable in the extracted statements for this period."}},{"period":"2022","end":"2023-01-01","values":{"gross_margin":60.082637291496944,"operating_margin":22.425691960497875,"roic":5.1173681995999925,"fcf_margin":17.941121231757016,"sbc_revenue":1.5555787720475314},"issues":{"peg":"TTM earnings per diluted share growth is zero or negative; a growth-adjusted multiple requires positive growth.","pfcf_growth":"TTM FCF per diluted share growth is zero or negative; a growth-adjusted multiple requires positive growth.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","roiic":"Invested capital did not increase versus the prior year. ROIIC requires a positive increase.","roic_wacc":"Enter a WACC assumption from 0 to 100%."}},{"period":"2023","end":"2023-12-31","values":{"gross_margin":null,"operating_margin":10.927258376533455,"roic":2.6585247856082526,"fcf_margin":0.36007069077657006,"sbc_revenue":1.5055055841132623},"issues":{"pfcf_growth":"TTM FCF per diluted share growth is zero or negative; a growth-adjusted multiple requires positive growth.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","gross_margin":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","roiic":"Invested capital did not increase versus the prior year. ROIIC requires a positive increase.","roic_wacc":"Enter a WACC assumption from 0 to 100%."}},{"period":"2024","end":"2024-12-29","values":{"gross_margin":null,"operating_margin":12.585761441089849,"roic":3.0271393322152256,"fcf_margin":19.660467814096855,"sbc_revenue":1.372364543928079},"issues":{"peg":"TTM earnings per diluted share growth is zero or negative; a growth-adjusted multiple requires positive growth.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","gross_margin":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","roiic":"Invested capital did not increase versus the prior year. ROIIC requires a positive increase.","roic_wacc":"Enter a WACC assumption from 0 to 100%."}},{"period":"2025","end":"2025-12-28","values":{"gross_margin":null,"operating_margin":12.486996905867578,"roic":3.3209405733942066,"fcf_margin":17.836201104251987,"sbc_revenue":0.7999507011604486},"issues":{"peg":"TTM earnings per diluted share growth is zero or negative; a growth-adjusted multiple requires positive growth.","pfcf_growth":"TTM FCF per diluted share growth is zero or negative; a growth-adjusted multiple requires positive growth.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","gross_margin":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","roiic":"Invested capital did not increase versus the prior year. ROIIC requires a positive increase.","roic_wacc":"Enter a WACC assumption from 0 to 100%."}}],"sources":[{"id":"filing-1","url":"https://www.sec.gov/Archives/edgar/data/31791/000003179126000012/revv-20251228.htm","publishedAt":"2026-02-24","sha256":"c642f0c908f15dbd2350c53f477c1df43cbfb162ad545a55b2526e503bd4c932","dateKind":"filed"},{"id":"filing-2","url":"https://www.sec.gov/Archives/edgar/data/31791/000003179126000027/revv-20260705.htm","publishedAt":"2026-08-11","sha256":"5da708bd4d45300ef68123365a11a95e886681070df018615f8b74012a2bc3aa","dateKind":"filed"},{"id":"filing-3","url":"https://www.sec.gov/Archives/edgar/data/31791/000119312526107266/d21831ddef14a.htm","publishedAt":"2026-03-16","sha256":"8287f26bebadccfcc8d32d1e94f4eafa135d52fcd3503d25b8839a731ec15222","dateKind":"filed"},{"id":"filing-4","url":"https://www.sec.gov/Archives/edgar/data/31791/000003179125000009/revv-20241229.htm","publishedAt":"2025-02-25","sha256":"c838ee1bb035f06729c3dedd86079146489fcfdaf877dd74956770e212991cb0","dateKind":"filed"},{"id":"filing-5","url":"https://www.sec.gov/Archives/edgar/data/31791/000003179124000004/pki-20231231.htm","publishedAt":"2024-02-27","sha256":"bd2b0d6f8d45a04e67c481517e65fe36d6a7bf9ae46264f22587b90f02f8833d","dateKind":"filed"},{"id":"filing-6","url":"https://www.sec.gov/Archives/edgar/data/31791/000003179126000019/revv-20260405.htm","publishedAt":"2026-05-12","sha256":"7032cd4d5f7dc3a6c9a267421feaa774cebf523663133070c666a40e6c49e683","dateKind":"filed"}],"history":[{"version":3,"updatedAt":"2026-10-18T16:35:43.872Z","verdict":"uncertain","value":null},{"version":2,"updatedAt":"2026-10-18T02:27:49.793Z","verdict":"uncertain","value":null},{"version":1,"updatedAt":"2026-10-18T02:18:02.026Z","verdict":null,"value":null}],"hasRequested":false,"requestStatus":"completed","researchIssue":null,"archivedMoat":null,"scope":"supported_catalog"}